Analyst Moves: BIIB, X, PFE - Presented by: The Aol. On Network

This morning, Goldman Sachs downgraded shares of Biogen (BIIB) from buy to neutral citing valuation. The stock has reached the firm's $215 price target, leaving less upside for investors.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 16.15 0.04 ▲ 0.25%
AAPL $ 130.14 1.19 ▲ 0.92%
TWTR $ 38.38 0.54 ▲ 1.43%
VALE $ 7.975 0.10 ▼ 1.18%
CYNI $ 4.69 1.04 ▲ 28.49%
PBR $ 9.68 0.15 ▲ 1.57%
QQQ $ 109.6399 0.59 ▲ 0.54%
CMCSA $ 59.115 0.71 ▲ 1.21%

As of 5/4/2015, 09:36 AM